Zhaoke Ophth-B (06622) announced that the National Medical Products Administration of China has recently accepted the new drug application for NVK002 (0.02% atropine sulfate ophthalmic solution), which is used to treat myopia progression in children. The new drug application is classified as a Class II innovative drug.